Trial Details
NoBasic Information
| Clinical ID | c5554 |
|---|---|
| Identifier | NL-OMON25521 |
| Trial Title | Microbiota targeted therapy as alternative for prednisolone and biologicals in IBD patients during the current COVID-19 threat: a prospective study addressing the safety of Budesonide in combination with rifaximin or the Crohns Disease Exclusion Diet (CDE |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NULL |
|---|---|
| Conditions | NULL |
| Interventions | The results of this prospective study may result in a safe treatment protocol during future pandemics, in which an alternative of immunosuppressive medication may reappear. |
Participant Information
| Sponsor | Nestl? 23/08/2021 |
|---|---|
| City | NULL |
| Country/Region | Andrea |
Enrollment Criteria
| Sex Requirement | NOT SPECIFIED |
|---|---|
| Age Requirement | NULL |
Study Design
| Study Type | Non-randomized controlled trial, Open (masking not used), N/A , unknown, Other |
|---|---|
| Phase | NULL |
Time Information
| Start Date | NULL |
|---|---|
| Primary Completion Date | NULL |
| Completion Date | NULL |